Phase II study of induction therapy with subcutaneous bortezomib, oral melphalan and predonisone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation - Phase II study of MP plus subcutaneous bortezomib for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation

Kanagawa Clinical Oncology Group0 个研究点目标入组 37 人开始时间: 2013年4月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Women in pregnancy or lactation; women who can not or intend to use appropriate contraceptive methods 2)Active and advanced cancer 3)steroid administration equivalent to 10mg prednisolone for other disease 4)psychiatric disease or psychological symptom 5)Positive for HBs antigen or able to detect HBV DNA 6)Positive for HCV antibody 7)Positive for HIV antibody 8)poorly controlled diabetes mellitus 9)poorly controlled hypertension 10)Cardiac amyloidosis 11)Angina; acute myocardial infarction last 6 months; heart failure or arrythmia that needs treatment 12)Interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema or pleural effusion that allows aspiration 13)Peripheral neuropathy Grade >=2; painful peripheral neuropathy 14)Severe drug allergy 15)The patient judged inappropriate to participate in this study

发起方

Kanagawa Clinical Oncology Group